May 13 that the Phase 2a outcomes of an oral alpha 4 integrin antagonist.

Ajinomoto announces Phase 2a results of oral alpha 4 integrin antagonist AJM300 in ulcerative colitis patients Ajinomoto Pharmaceuticals Co http://levitraprix.net/contactez-nous ., Ltd. announced on, may 13 that the Phase 2a outcomes of an oral alpha 4 integrin antagonist, AJM300, in patients with ulcerative colitis had been provided in the Joint Presidential Plenary Session at Digestive Disease Week 2014 held Might 3 – 6 in Chicago, IL, USA. In inflammatory bowel disease including ulcerative colitis, excessive infiltration of lymphocytes into the inflamed lesion is known to be linked to the disease progression. AJM300 has a new setting of action that prevents the adhesion and invasion of lymphocytes mainly to the inflamed lesion.